SCHEMBL5457907

SCHEMBL5457907

NC(=O)c1c(N(S)C(=O)Nc2cccnc2)sc2c1CCCC2

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.55
NPC1 O15118 8/20 0.55
ALDH1A1 P00352 8/20 0.55
RAB9A P51151 7/20 0.55
FLT3 P36888 5/20 0.55
POLB P06746 2/20 0.54
KDM4E B2RXH2 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
LMNA P02545 3/20 0.45
GAA P10253 1/20 0.45
HPGD P15428 1/20 0.44
TDP1 Q9NUW8 2/20 0.43
RCE1 Q9Y256 1/20 0.43
AMY1A P0DUB6 2/20 0.41
TP53 P04637 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MGAM O43451 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5456402 0.86 CFTR (0.43) MAPTNPC1ALDH1A1RAB9AFLT3
SCHEMBL5457899 0.77 ALDH1A1 (0.76) MAPTNPC1ALDH1A1RAB9AFLT3
SCHEMBL5451403 0.72 FLT3 (0.47) MAPTNPC1ALDH1A1RAB9AFLT3
SCHEMBL5457779 0.71 RAB9A (1.00) MAPTNPC1ALDH1A1RAB9AFLT3
SCHEMBL5448466 0.70 GAA (0.57) MAPTALDH1A1FLT3KDM4EMEN1
SCHEMBL6815662 0.69 L3MBTL1 (0.48) NPC1RAB9ALMNAGAATP53
SCHEMBL5448493 0.67 CFTR (0.45) FLT3
SCHEMBL5465670 0.66 RAB9A (0.53) MAPTNPC1ALDH1A1RAB9AFLT3
SCHEMBL5447424 0.65 CFTR (0.46) MAPTNPC1RAB9AKDM4EMEN1
SCHEMBL5463139 0.65 CFTR (0.55) MAPTNPC1ALDH1A1RAB9AFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 MAPT 21/4885NPC1 2627/4885ALDH1A1 1153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.